Table 4.

Analysis of one-time incident HPV infections by dose cohorts and age.

Type of HPV infection/Dose received	HPV incidence
	Participants with ≥ one samples tested
	Age group	Women assessed	Women with incident infections	Proportion of incidence (%, 95% CI)
HPV 16/18 infections
3-dose	10–14	412	4	1.0	(0.3–2.5)
	15–18	701	7	1.0	(0.4–2.0)
2-dose	10–14	262	2	0.8	(0.1–2.7)
	15–18	661	4	0.6	(0.2–1.5)
HPV 6/11 infections
3-dose	10–14	412	4	1.0	(0.3–2.5)
	15–18	701	3	0.4	(0.1–1.2)
2-dose	10–14	262	0	0.0
	15–18	661	3	0.5	(0.1–1.3)
Non-vaccine-targeted HPV 31, 33 and 45 infections
3-dose	10–14	412	14	3.4	(1.9–5.6)
	15–18	701	40	5.7	(4.1–7.7)
2-dose	10–14	262	10	3.8	(1.8–6.9)
	15–18	661	36	5.4	(3.8–7.5)
Non-vaccine-targeted high-risk HPV (31/33/35/39/45/51/52/56/58/59/68) infections
3-dose	10–14	412	45	10.9	(8.1–14.3)
	15–18	701	89	12.7	(10.3–15.4)
2-dose	10–14	262	42	16.0	(11.8–21.0)
	15–18	661	101	15.3	(12.6–18.3)
Any HPV (16/18/6/11/26/31/33/35/39/45/51/52/53/56/58/59/66/68/70/73/82) infection
3-dose	10–14	412	74	18.0	(14.4–22.0)
	15–18	701	111	15.8	(13.2–18.8)
2-dose	10–14	262	50	19.1	(14.5–24.4)
	15–18	661	120	18.2	(15.3–21.3)

HPV: human papilloma virus; CI: confidence interval.